Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with…

By N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi, Takahiro Kakehi. Blood, 2008

767 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/e89b09f26725be8c4ee66dd266eebe06baec9c55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Pathology and Forensic Medicine

In Rheumatology

Citations in the corpus

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018, background): “Suboptimal response of neurotoxicity to tocilizumab may be due to elevation of multiple cytokines in addition to IL6 in patients with severe neurotoxicity, or because tocilizumab induces a transient increase of serum IL6 which might increase CNS levels (27).”
IL-6 in inflammation, immunity, and disease. (2014, background): “It was found that if free serum concentration of tocilizumab is maintained at more than 1 mg/ml, CRP remains negative (Nishimoto et al. 2008), indicating that IL-6 plays a major role in the induction of CRP expression and that IL-6 may be involved in the development of almost all chronic inflammator”
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia (2016, background): “In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy (2020, unknown): “IL-6 serum levels increased, similarly to what was reported after TCZ administration in patients with Rheumatoid Arthritis and Castleman disease [22].”
Tocilizumab treatment in COVID‐19: A single center experience (2020, background): “Actually, IL‐6 is mainly eliminated via IL‐6R‐mediated clearance.(8) Binding of TCZ to IL‐6R inhibits receptor‐mediated clearance of IL‐6, leading to its accumulation in serum.”
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. (2011, background): “Patients treated with tocilizumab show only a mild accumulation of IL-6, due to blockade of IL-6R– dependent internalization, which regulates IL-6 clearance (118).”
Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (2017, background): “094 40–60 years 42 (66) 8 (13) 14 (22) 64 >60 years 27 (64) 7 (17) 8 (19) 42 Sex, n (%) Male 59 (63) 17 (18) 17 (18) 93 0.”
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “Serum levels of CRP remain suppressed whenever free tocilizumab levels are above 1 μg/mL, suggesting that CRP is a downstream biomarker that allow to estimate the duration and magnitude of IL-6 suppression in vivo (Nishimoto et al., 2008).”
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “Clinical research suggests that tocilizumab does not inhibit IL-6 production directly, instead, as long as free tocilizumab is detectable, the sIL-6R is saturated with tocilizumab [250].”